FLT3-TKD基因突变对急性髓系白血病预后影响的Meta分析

Abstract
Figure/Table
References (22)
Related Citation (15)

Download: PDF (0 KB) HTML (44 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To evaluate the influence of FLT3-TKD mutation on the prognosis of acute myeloid leukemia(AML)using meta-analysis.Methods “FLT3-TKD”,“D835” and “Acute Myeloid Leukemia” as English terms were searched in Pubmed.“FLT3-TKD”,“D835” and “Jixing Suixi Baixuebing” (in Chinese characters;acute myeloid leukemia)were searched in China National Knowledge Infrastructure and Wanfang database.The retrieval time was from the inception to April 14,2018.Results Eight articles were included,and 7 in English-version and 1 in Chinese,with a total of 3430 patients.Meta-analysis showed that there were no statistical differences in a complete response rate(CR)(HR=1.06,95%CI 0.99-1.14,P=0.07)and disease-free survival(DFS)(HR=1.44,95%CI=0.99-2.09,P=0.06).The overall survival rate(OS)(HR=1.37,95%CI=1.12-1.67,P=0.002)was displayed a statistical difference between the two groups.Conclusion FLT3-TKD gene mutation may be a risk factor for poor prognosis in patients with AML.

Key words： Fms-like tyrosine kinase 3-kinase domain point mutation Acute myeloid leukemia Prognosis Metaanalysis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2019/V26/I3/7

[1]	Dohner H，Estey EH，Amadori S，et al.Diagnosis and management of acute myeloid leukemia in adults：recommendations from an international expert panel，on behalf of the European LeukemiaNet[J].Blood，2010，115（3）：453-474.
[2]	Murphy K，Levis M，Hafez M，et al.Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay[J].J Mol Diagn，2003，5（2）：96-102.
[3]	Cook D，Reed D.Appraising the quality of medical education research methods：the Medical Education Research Study Quality Instrument and the Newcastle-Ottawa Scale-Education[J].Acad Med，2015，90（8）：1067-1076.
[4]	乔曼，李渭阳，孙爱宁，等.核心结合因子相关性急性髓系白血病中酪氨酸激酶突变分析及其临床意义[J].中华血液学杂志，2011，32（10）：679-683.
[5]	Whitman SP，Ruppert AS，Radmacher MD，et al.FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications[J].Blood，2008，111（3）：1552-1159.
[6]	Thiede C，Steudel C，Mohr B，et al.Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia：association with FAB subtypes and identification of subgroups with poor prognosis[J].Blood，2002，99（12）：4326-4335.
[7]	Mead AJ，Linch DC，Hills RK，et al.FLT3 tyrosine kinase domainmutationsarebiologicallydistinctfromandhaveasignificantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia[J].Blood，2007，110（4）：1262-1270.
[8]	Janke H，Pastore F，Schumacher D，et al.Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia[J].PLoS One，2014，9（3）：e89560.
[9]	Santos FP，Jones D，Qiao W，et al.Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia[J].Cancer，2011，117（10）：2145-2155.
[10]	Allen C，Hills RK，Lamb K，et al.The importance of relative mutant level for evaluating impact on outcome of KIT，FLT3 and CBL mutations in core-binding factor acute myeloid leukemia[J].Leukemia，2013，27（9）：1891-1901.
[11]	Yamamoto Y，Kiyoi H，Nakano Y，et al.Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies[J].Blood，2001，97（8）：2434.
[12]	Lwenberg B.Acute myeloid leukemia：the challenge of capturing disease variety[J].Hematology Am Soc Hematol Educ Program，2008，2008（1）：1-11.
[13]	Gaballa S，Saliba R，Oran B，et al.Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation[J].Am J Hematol，2017，92（4）：331-337.
[14]	Rubio P，Campos B，Digiorge J，et al.NPM1，FLT3 and CEBPAmutationsinpediatricpatientswithAMLfromArgentina：incidence and prognostic value[J].Int J Hematol，2016，104（5）：582-590.
[20]	LevisM，SmallD.FLT3：itdoesmatterinleukemia[J].Leukemia，2003，17（9）：1738-1752.
[15]	Mr zek K，Marcucci G，Paschka P，et al.Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics：are we ready for a prognostically prioritized molecular classification?[J].Blood，2007，109（2）：431-448.
[16]	Bacher U，Haferlach C，Kern W，et al.Prognostic relevance of FLT3-TKD mutations in AML：the combination matters—an analysis of 3082 patients[J].Blood，2008，111（5）：2527.
[17]	Fathi AT，Arowojolu O，Swinnen I，et al.A potential therapeutic target for FLT3-ITD AML：PIM1 kinase[J].Leuk Res，2012，36（2）：224-231.
[18]	Radomska HS，Alberich-Jordà M，Will B，et al.Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPα[J].J Clin Invest，2012，122（8）：2955-2966.
[19]	Marcucci G，Haferlach T，Dohner H.Molecular genetics of adult acute myeloid leukemia：prognostic and therapeutic implications[J].J Clin Oncol，2011，29（5）：475-486.
[21]	Boddu P，Kantarjian H，Borthakur G，et al.Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group[J].Blood Adv，2017，1（19）：1546-1550.
[22]	Leung A，Man C，Kwong Y.FLT3 inhibition：a moving and evolving target in acute myeloid leukaemia[J].Leukemia，2013，27（2）：260-268.